Updating results

570 results

Sort: Relevance | Date

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: 09 December 2020

Technology appraisal guidance In development

Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

In development [GID-TA10494] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Technology appraisal guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 02 December 2020

Technology appraisal guidance In development

Encorafenib with binimetinib and cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer ID1598

In development [GID-TA10496] Expected publication date: TBC

Technology appraisal guidance In development

Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable ID1564

In development [GID-TA10478] Expected publication date: 10 February 2021

Technology appraisal guidance In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 08 July 2020

Diagnostics guidance In development

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Technology appraisal guidance In development

Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: 26 August 2020

NICE guideline In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide for previously treated follicular lymphoma and marginal zone lymphoma ID1374

In development [GID-TA10323] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Mogamulizumab for treated mycosis fungoides or S├ęzary syndrome T-cell lymphoma ID1405

In development [GID-TA10305] Expected publication date: 26 August 2020

Technology appraisal guidance In development

Veliparib for treating HER2-negative, BRCA-positive breast cancer ID1404

In development [GID-TA10327] Expected publication date: TBC

Technology appraisal guidance In development

Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

In development [GID-IPG10067] Expected publication date: TBC

Interventional procedures guidance In development

Atrial fibrillation: management

In development [GID-NG10100] Expected publication date: 17 September 2020

NICE guideline In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Subarachnoid haemorrhage due to ruptured aneurysms

In development [GID-NG10097] Expected publication date: 03 February 2021

NICE guideline In development

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]

In development [GID-HST10015] Expected publication date: TBC

Highly specialised technologies guidance In development

Dupilumab for treating severe asthma

In development [GID-TA10276] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Patiromer for treating hyperkalaemia [ID877]

In development [GID-TA10273] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2019)

In development [GID-NG10087] Expected publication date: 13 November 2019

NICE guideline In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Diabetic foot infection: antimicrobial prescribing

In development [GID-NG10132] Expected publication date: 11 October 2019

Antimicrobial prescribing guideline In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 13 October 2020

Antimicrobial prescribing guideline In development

Cellulitis and erysipelas: antimicrobial prescribing

In development [GID-NG10131] Expected publication date: 27 September 2019

Antimicrobial prescribing guideline In development

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)

In development [GID-TA10366] Expected publication date: TBC

Technology appraisal guidance In development

Ramucirumab for previously treated advanced hepatocellular carcinoma [860]

In development [GID-TA10364] Expected publication date: TBC

Technology appraisal guidance In development

Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: 11 December 2019

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development

Maternal health

In development [GID-QS10077] Expected publication date: TBC

Quality standard In development

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

In development [GID-TA10328] Expected publication date: TBC

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory mantle cell lymphoma ID1313

In development [GID-TA10312] Expected publication date: 09 December 2020

Technology appraisal guidance In development

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352

In development [GID-TA10319] Expected publication date: TBC

Technology appraisal guidance In development

Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

In development [GID-TA10316] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

In development [GID-TA10351] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Sotagliflozin, in combination with insulin, for treating type 1 diabetes [ID1376]

In development [GID-TA10376] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma ID1276

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

Suspected neurological conditions

In development [GID-QS10082] Expected publication date: 03 July 2020

Quality standard In development

Cerebral palsy in adults

In development [GID-QS10080] Expected publication date: 23 January 2020

Quality standard In development

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer

In development [GID-MT526] Expected publication date: 16 March 2020

Medical technologies guidance In development

Specialist neonatal respiratory care for babies born preterm

In development [GID-QS10137] Expected publication date: 20 March 2020

Quality standard In development